Posted by Michael Wonder on 12 Sep 2022
Acadia Pharmaceuticals announces trofinetide new drug application for the treatment of Rett syndrome has been accepted for filing and review by US FDA
12 September 2022 - Prescription Drug User Fee Act action date set for 12 March 2023.
Acadia Pharmaceuticals today announced that the US FDA has accepted for filing its new drug application of trofinetide for the treatment of Rett syndrome.
